Home » Newsletters » BioWorld Science

BioWorld Science

May 3, 2013

View Archived Issues

New small-molecule enzymatic inhibitors targeting primary human tumors

Adenovirus-based immunotherapy for chronic hepatitis B

New electrochemical immunosensor for diagnosis of inflammatory intestinal disease

Yakult Honsha synthesizes novel protein kinase inhibitors

French team presents new caspase activators

BioSavita and Quanta BioDesign enter collaboration to BioSuperior therapeutics

Dana-Farber and Evotec form oncology collaboration focusing on epigenetic targets

Servier to use Afraxis' ESP Technology for drug discovery

CCT-271850 demonstrates in vitro and in vivo activity

Tolero acquires worldwide license to Sanofi's alvocidib

OGX-427 to be studied as part of combination therapy for pancreatic cancer

Genentech evaluates antibody-drug conjugate for lung and ovarian cancer

Ligand acquires financial rights to portfolio of programs from Selexis

FDA approves use of Actemra in polyarticular juvenile idiopathic arthritis

FDA approves Raptor Pharmaceutical's treatment for nephropathic cystinosis

FDA issues complete response letter declining approval of Probuphine

Roche discloses new CRAC modulators

Novel PDE10A inhibitors prepared by Lundbeck

Enanta Pharmaceuticals synthesizes novel HCV NS5A inhibitors

Ascletis Pharmaceuticals obtains rights to HIV drug in China

DiaMedica begins first-in-human trial of DM-199

Forest Laboratories and Almirall report data from phase III AUGMENT COPD study

Daratumumab receives FDA breakthrough therapy designation

Vyvanse obtains FDA approval for maintenance treatment in children with ADHD

Omadacycline receives another QIDP designation

FDA committee votes against approval of tivozanib

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...